Hospira Expands Recall of Propofol and Liposyn

Hospira is voluntarily expanding its recall of its Propofol Injectable Emulsion 1% and Liposyn products, including Liposyn II 10%, Liposyn II 20%, Liposyn III 10%, Liposyn III 20% and Liposyn III 30%, due to particulate matter found in some of the containers, according to an alert from the U.S. Food and Drug Administration.

The affected lot numbers are:

Propofol — lot numbers beginning with 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 82, 83, 84 and 85.
Liposyn — lot numbers beginning with 72, 73, 74, 75, 76, 77, 78, 82, 83, 84 and 85.

The affected lots of propofol were distributed between March 2008 and April 2010. The affected lots of Liposyn were distributed between Dec. 2008 and April 2010.

Read the FDA’s alert about the Hospira recall.

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Next Up in GI & Endoscopy

Hospira Expands Recall of Propofol and Liposyn

Next Up in GI & Endoscopy

Ohio GI practice acquired

2026 gastroenterology fellowship match: A breakdown

How Orlando Health is reshaping bariatric care

Interoperability’s next chapter: How healthcare leaders are reenvisioning connected care

Next Up in GI & Endoscopy

Ohio GI practice acquired

2026 gastroenterology fellowship match: A breakdown

How Orlando Health is reshaping bariatric care

Join the 40,000+ ASC leaders who start their day with Becker's